Compare · AS vs SILO
AS vs SILO
Side-by-side comparison of Amer Sports Inc. (AS) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AS and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- AS is the larger of the two at $19.13B, about 3304.7x SILO ($5.8M).
- Over the past year, AS is down 9.7% and SILO is down 43.6% - AS leads by 34.0 points.
- SILO has hit the wire 10 times in the past 4 weeks while AS has been quiet.
- AS has more recent analyst coverage (25 ratings vs 0 for SILO).
PerformanceAS-9.66%SILO-43.63%
2025-07-15+0.00%2026-07-15
- Company
- Amer Sports Inc.
- Silo Pharma Inc.
- Price
- $35.59+3.67%
- $4.82-7.22%
- Market cap
- $19.13B
- $5.8M
- 1M return
- +0.38%
- -27.41%
- 1Y return
- -9.66%
- -43.63%
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 0
Latest AS
- Chief Executive Officer Zheng Jie (James) exercised 500,000 units of Ordinary Shares at a strike of $7.68 and sold $17,210,450 worth of Ordinary Shares (500,000 units at $34.42) (SEC Form 4)
- Chief Strategy Officer Chen Wen-Chang (Victor) sold $465,764 worth of Ordinary Shares (13,075 units at $35.62), decreasing direct ownership by 8% to 149,821 units (SEC Form 4)
- CEO of Arc'teryx Equipment Haselden Stuart exercised 200,000 units of Ordinary Shares at a strike of $12.51 and sold $7,656,766 worth of Ordinary Shares (215,275 units at $35.57), closing all direct ownership in the company (SEC Form 4)
- SEC Form 144 filed by Amer Sports Inc.
- Chief Financial Officer Page Andrew E sold $3,867,726 worth of Ordinary Shares (105,230 units at $36.75) and exercised 97,485 units of Ordinary Shares at a strike of $14.19, decreasing direct ownership by 65% to 4,083 units (SEC Form 4)
- SEC Form 144 filed by Amer Sports Inc.
- SEC Form 6-K filed by Amer Sports Inc.
- Amer Sports Reports First Quarter 2026 Financial Results, Raises Full Year Revenue, Margin, and EPS Guidance
- SEC Form 4 filed by Director Yiu Kin Wah Stephen
- SEC Form 4 filed by Director Salzer Bruno
Latest SILO
- SEC Form D filed by Silo Pharma Inc.
- Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form SCHEDULE 13G filed by Silo Pharma Inc.
- Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
- SEC Form DEFA14A filed by Silo Pharma Inc.
- SEC Form DEF 14A filed by Silo Pharma Inc.
- Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
- Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial